✦ LIBER ✦

An evidence-based risk-benefit assessment of adalimumab, etanercept, and infliximab in psoriasis

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of drug survival rates for ad

✍ R. Gniadecki; K. Kragballe; T.N. Dam; L. Skov 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

Onychomycosis in patients of nail psoria

✍ Al-Mutairi, Nawaf; Nour, Tarek; Al-Rqobah, Duha 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 197 KB

Acamprosate and naltrexone treatment for

✍ Barbara J. Mason 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Treatment effect of adalimumab and infli

✍ Shinji NODA; Kyoko MIZUNO; Makoto ADACHI 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 221 KB

Efficacy of adalimumab, etanercept, and

✍ Brodszky, V.; Pentek, M.; Gulacsi, L. 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 125 KB

Efficacy and safety of adalimumab in pat

✍ Robert Bissonnette; Chantal Bolduc; Yves Poulin; Lyn Guenther; Charles W. Lynde; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 414 KB